Search

Roche Holding AG

Затворен

СекторЗдравеопазване

293.8 -2.59

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

291

Максимум

301.6

Ключови измерители

By Trading Economics

Приходи

6.3B

Продажби

31B

P/E

Средно за сектора

29.748

63.778

Дивидентна доходност

3.1

Марж на печалбата

20.347

Служители

103,249

EBITDA

11B

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

3.10%

2.39%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

233B

Предишно отваряне

296.39

Предишно затваряне

293.8

Настроения в новините

By Acuity

18%

82%

176 / 386 Класиране в Healthcare

Roche Holding AG Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

12.03.2025 г., 09:23 ч. UTC

Значими двигатели на пазара

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

30.01.2025 г., 09:36 ч. UTC

Печалби

Roche Expects Growth to Continue This Year After Sales, Earnings Beat Forecasts -- Update

30.01.2025 г., 06:32 ч. UTC

Печалби

Roche Expects Sales, Earnings Growth After Better-Than-Expected Results

3.04.2025 г., 08:41 ч. UTC

Пазарно говорене

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

3.04.2025 г., 07:51 ч. UTC

Пазарно говорене

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

31.03.2025 г., 09:31 ч. UTC

Горещи акции

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

13.03.2025 г., 07:46 ч. UTC

Пазарно говорене

Roche's Zealand Pharma Deal Signals Commitment to Obesity Drug Market -- Market Talk

12.03.2025 г., 16:34 ч. UTC

Топ новини

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal -- Update

12.03.2025 г., 08:51 ч. UTC

Пазарно говорене

Roche's Multiple-Sclerosis Drug Sales Potential Fuels Rating Upgrade -- Market Talk

12.03.2025 г., 08:18 ч. UTC

Пазарно говорене

Roche's Obesity Deal With Zealand Pharma Makes Sense, Vontobel Says -- Market Talk

13.02.2025 г., 11:43 ч. UTC

Пазарно говорене

Roche's Growth Fueled by Key Drugs, Promising Pipeline -- Market Talk

30.01.2025 г., 07:56 ч. UTC

Пазарно говорене
Печалби

Roche Delivered Solid Results But Diagnostics' Profitability Disappoints -- Market Talk

30.01.2025 г., 06:04 ч. UTC

Печалби

Roche Expects 2025 EPS Growth in High Single Digit Range at Constant Currency

30.01.2025 г., 06:04 ч. UTC

Печалби

Roche Expects 2025 Sales Increase in Mid Single Digit Range at Constant Currency

30.01.2025 г., 06:04 ч. UTC

Печалби

Roche Issues 2025 View

30.01.2025 г., 06:03 ч. UTC

Печалби

Roche Raises Dividend to CHF9.70 Vs CHF9.60

30.01.2025 г., 06:03 ч. UTC

Печалби

Roche 2024 Core Operating Profit CHF20.82B

30.01.2025 г., 06:03 ч. UTC

Печалби

Roche 2024 Net Pft CHF9.19B

30.01.2025 г., 06:02 ч. UTC

Печалби

Analysts Saw 2024 Core EPS at CHF18.59

30.01.2025 г., 06:02 ч. UTC

Печалби

Roche 2024 Core EPS CHF18.80

30.01.2025 г., 06:02 ч. UTC

Печалби

Roche 2024 Sales EUR60.50B

30.01.2025 г., 06:02 ч. UTC

Печалби

Analysts Saw Roche 2024 Revenue at CHF60.41B

30.01.2025 г., 06:01 ч. UTC

Печалби

Roche 2024 Sales CHFB

28.01.2025 г., 10:30 ч. UTC

Топ новини

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

28.01.2025 г., 07:24 ч. UTC

Пазарно говорене

Roche's Breast Cancer Drug Extends Life of Patients -- Market Talk

15.01.2025 г., 10:22 ч. UTC

Пазарно говорене

Swiss Companies Pay Record Level of Dividends as Buybacks Fall -- Market Talk

8.01.2025 г., 06:15 ч. UTC

Придобивния, сливания и поглъщания

Roche: 66.11% of Poseida's Shares Were Validly Tendered in Offer

8.01.2025 г., 06:12 ч. UTC

Придобивния, сливания и поглъщания

Roche Intends to Complete Acquisition of Poseida Therapeutics Later Wednesday

16.12.2024 г., 22:03 ч. UTC

Топ новини

Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com

13.12.2024 г., 16:36 ч. UTC

Пазарно говорене

Swiss Equities an Overweight Pick Next Year -- Market Talk

Roche Holding AG Прогноза

Настроение

By Acuity

176 / 386 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.